Difference between revisions of "Case Studies/GlaxoSmithKline"
(Created page with "{{Case Study |Description=GlaxoSmithKline (a UK pharmaceutical company) has waived all copyright restrictions to its malaria data set, which includes more than 13,000 compounds k...") |
|||
| Line 1: | Line 1: | ||
{{Case Study | {{Case Study | ||
| − | |Description=GlaxoSmithKline (a UK pharmaceutical company) has waived all copyright restrictions to its malaria data set, which includes more than 13, | + | |Description=GlaxoSmithKline (a UK pharmaceutical company) has waived all copyright restrictions to its malaria data set, which includes more than 13,500 compounds known to be active against malaria. |
|Mainurl=http://www.ebi.ac.uk/chemblntd/#tcams_dataset | |Mainurl=http://www.ebi.ac.uk/chemblntd/#tcams_dataset | ||
|Author=ChEMBL-NTD, GlaxoSmithKline | |Author=ChEMBL-NTD, GlaxoSmithKline | ||
| Line 8: | Line 8: | ||
|Format=Data | |Format=Data | ||
|Country=United Kingdom | |Country=United Kingdom | ||
| + | |Quote=Providing access to this level of information sees GSK set what I would hope to be a new trend that could revolutionise the urgent search for new medicines to tackle malaria. By sharing data, we start to build up a public database of knowledge that should be as powerful as the human genome databases. | ||
| + | |Quote_Attribution=Timothy Wells, Chief Scientific Officer of the Medicines for Malaria Venture (http://www.gsk.com/responsibility/access/rnd-neglected-tropical-diseases.htm) | ||
}} | }} | ||
== Overview == | == Overview == | ||
| Line 17: | Line 19: | ||
== Motivations == | == Motivations == | ||
| + | From GSK's [http://www.gsk.com/responsibility/access/rnd-neglected-tropical-diseases.htm announcement]: | ||
| + | <blockquote>"By making this information publicly available, GSK hopes that many other scientists will review this information and analyse the data faster than we could on our own. Hopefully, this will lead to additional research that could help drive the discovery of new medicines. We would also encourage other groups, including academics and pharmaceutical companies, to make their own compounds and related information publicly available. | ||
| + | |||
| + | <br/><br/>This is essentially an example of ‘open source’ being applied to drug discovery. We know that data increases in value when connected with other data and that the more eyes looking at a problem, the more potential solutions may arise."</blockquote> | ||
== Media == | == Media == | ||
Revision as of 20:37, 20 August 2010
Providing access to this level of information sees GSK set what I would hope to be a new trend that could revolutionise the urgent search for new medicines to tackle malaria. By sharing data, we start to build up a public database of knowledge that should be as powerful as the human genome databases. — Timothy Wells, Chief Scientific Officer of the Medicines for Malaria Venture (http://www.gsk.com/responsibility/access/rnd-neglected-tropical-diseases.htm)
Overview
GlaxoSmithKline is a UK pharmaceutical company that has released a data set of 13,500 known compounds known to be active against malaria. The data set is called Tres Cantos Antimalarial (TCAMS), and is available from the ChEMBL-NTD database, "a repository for Open Access primary screening and medicinal chemistry data directed at neglected diseases - endemic tropical diseases of the developing regions of the Africa, Asia, and the Americas."
License Usage
GlaxoSmithKline has waived all copyright restrictions to its malaria data set under the CC0 public domain waiver.
Motivations
From GSK's announcement:
"By making this information publicly available, GSK hopes that many other scientists will review this information and analyse the data faster than we could on our own. Hopefully, this will lead to additional research that could help drive the discovery of new medicines. We would also encourage other groups, including academics and pharmaceutical companies, to make their own compounds and related information publicly available.
This is essentially an example of ‘open source’ being applied to drug discovery. We know that data increases in value when connected with other data and that the more eyes looking at a problem, the more potential solutions may arise."
